Drugs / allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells
allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07139509 | Oct 2024 → Jul 2028 expected | plasma cell myeloma | Xi'an No.3 Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07139509 ↗ |
| Modality | Cell therapy | “allogeneic cord blood-derived CAR-T cell drug” NCT07139509 ↗ |
| Route | Intravenous | “Route of Administration: Single intravenous injection” NCT07139509 ↗ |